FY2025 EPS Estimates for Medifast Reduced by Zacks Research

Medifast Inc (NYSE:MED) – Research analysts at Zacks Research cut their FY2025 EPS estimates for Medifast in a note issued to investors on Monday, November 24th. Zacks Research analyst Team now anticipates that the specialty retailer will earn ($1.08) per share for the year, down from their prior forecast of $0.02. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at $0.04 EPS, Q3 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.07) EPS.

A number of other research firms also recently issued reports on MED. Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Medifast from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $16.50.

Medifast Stock Up 0.1%

MED opened at $10.92 on Thursday. Medifast has a 52 week low of $10.36 and a 52 week high of $21.98. The stock has a market cap of $120.05 million, a PE ratio of 34.14 and a beta of 0.82. The business has a 50 day moving average of $12.61 and a 200-day moving average of $13.38.

Medifast (NYSE:MED) last posted its quarterly earnings data on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.20). Medifast had a net margin of 0.76% and a return on equity of 2.00%. The firm had revenue of $89.41 million for the quarter, compared to the consensus estimate of $84.10 million. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS.

Institutional Investors Weigh In On Medifast

A number of institutional investors have recently modified their holdings of MED. PNC Financial Services Group Inc. increased its holdings in shares of Medifast by 261.8% during the second quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer’s stock valued at $28,000 after acquiring an additional 1,448 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Medifast by 370.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,144 shares of the specialty retailer’s stock valued at $30,000 after purchasing an additional 1,688 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP purchased a new position in Medifast in the third quarter worth about $37,000. Finally, Strs Ohio bought a new position in shares of Medifast in the first quarter worth approximately $78,000. 95.51% of the stock is owned by hedge funds and other institutional investors.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.